Candel Therapeutics Director Adds $3 Million Stake as Company Prices $100M Offering
Director Paul B. Manning bought 550,458 shares of Candel Therapeutics (NASDAQ: CADL) on February 23, 2026, paying $5.45 per share for a total of $2,999,996. The transaction occurred while the stock was trading at $5.15. Manning's direct and indirect holdings, plus recent company filings, outline both insider accumulation and a $100 million public o…